FEBS Letters · 1991 · 28 citations · 17 references
PharmacyBiochemistryMedicinal ChemistryDrug DesignDrug DiscoveryStructural BiologyAnticoagulant TherapyLigand BindingPeptide Drug DiscoveryPeptidomimetic DesignProtein StructureProtein-ligand BindingAntithrombin FunctionCatalytic Site ArchitectureChemical Structure-activity RelationshipsFibrinogen BindingPeptide InteractionsPeptide Structure - Activity RelationshipsStructure-based PeptidomimeticsThrombin Inhibition
Using hirudin as a model, a novel class of bivalent thrombin inhibitors has been designed and characterized (Maraganore et al. (1990) Biochemistry 29, 7095-7101). These peptides, designated 'hirulogs', interact with both thrombin's catalytic center and its anion-binding exosite for fibrinogen recognition. In order to investigate structure-activity relationships in hirulog peptides, a number of peptide and peptidomimetic derivatives with alterations in catalytic-site binding and anion-binding exosite binding moieties were prepared. Replacements or modifications in the catalytic site and exosite binding moieties were achieved with the consequences of maintaining or improving antithrombin activity. In addition to showing improved affinity for thrombin, some derivatives with Ki's in the sub-nanomolar range showed increased anticoagulant activities. These findings highlight the versatility of hirulog peptides in their bivalent interactions with thrombin.
17
Wolfram Bode, Irmgard Mayr, Ulrich Baumann et al. · The EMBO Journal · 1989 · 893 citations · Full text
The Structure of a Complex of Recombinant Hirudin and Human α-Thrombin
T.J. Rydel, Kirubhagaran Ravichandran, A. Tulinsky et al. · Science · 1990 · 716 citations
Kinetics of the inhibition of thrombin by hirudin
Stuart R. Stone, Jan Hofsteenge · Biochemistry · 1986 · 584 citations